EGFR and neoplasm: Other contributing factors could be the use of very low cut-off value of EGFR positivity in the earlier studies (i.e. EGFR positivity when immunostaining is present in ≥1% of tumour cells) [29, 30], and discordance between the expression of EGFR in the primary tumour and the metastatic sites [31, 32].